Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated robust sales growth by selling 7,233 nanochannel array flowcells in 2Q25, representing a 17% increase from the previous year, and followed this with 8,390 sales in 3Q25, reflecting a 7% rise year-over-year. The company reported an 11% year-over-year increase in adjusted combined revenue for consumables, software, and remaining services in 2Q25, with consumables and software revenues specifically growing by 16%. Additionally, Bionano's outlook for new OGM installations in FY2025 has been raised to 20-25, indicating strong confidence in continued adoption of its technologies across various global regions, including Japan.

Bears say

Bionano Genomics faces several fundamental challenges that contribute to the negative outlook on its stock, including the risk of lower-than-anticipated market uptake and utilization of its Saphyr system. Additionally, the company's reliance on securing additional capital to fund operations introduces further uncertainty, as there is a possibility of dilution for shareholders. These risks, combined with a conservative expected revenue multiple, underscore the challenges the company faces in achieving its projected sales and sustaining financial health.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.